Le Lézard
Classified in: Health
Subject: FDA

BIOTRONIK Announces FDA Approval of Renamic Neo with LiveSupport Software


LAKE OSWEGO, Ore., April 26, 2022 /PRNewswire/ -- BIOTRONIK, Inc. announced today it has received U.S. Food and Drug Administration (FDA) approval of Renamic Neo, the company's state-of-the-art programmer for implanted cardiac rhythm management devices such as ICDs, pacemakers, and implantable cardiac monitors.

In addition to its programming functions, Renamic Neo now offers LiveSupport, which allows clinicians to share the programmer screen with, or grant programmer control to, BIOTRONIK technical support personnel at remote locations. Renamic Neo is also compatible with BIOTRONIK's ReportShare and EHR DataSync to allow secure and easy integration of programmer data into hospitals' EHR systems.

"The Renamic Neo programmer represents another advancement in providing clinicians with better tools to improve patient care," said Dr. Sei Iwai, Section Chief Cardiac Electrophysiology, at Westchester Medical Health Network, Valhalla, New York. "The LiveSupport feature, ReportShare, and EHR DataSync, plus all the connectivity options in this programmer, can improve our workflow and response time. The Renamic Neo programmer is exactly the tool we need in our device clinic."

The Renamic Neo programmer boasts a 12" high-resolution, high-contrast, LCD touch screen display, a built-in analyzer, and battery-powered portability, as well as various connectivity options. In addition, Renamic Neo is significantly lighter and smaller than its predecessor.

Renamic Neo will soon be available in the United States to hospitals and clinics that implant BIOTRONIK cardiac rhythm management devices.

For more information, visit: www.biotronik.com 

About BIOTRONIK
BIOTRONIK is a leading medical device company that develops trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.

Follow BIOTRONIK on:
Twitter: @BIOTRONIK_US
LinkedIn: www.linkedin.com/company/biotronik 
YouTube: www.youtube.com/BIOTRONIKUS

SOURCE BIOTRONIK


These press releases may also interest you

at 08:17
Global Landmarks Illuminate for World NF Awareness Day as Children's Tumor Foundation Highlights its "Make NF Research Visible" Campaign
The Children's Tumor Foundation (CTF) announces nearly 400 world-famous buildings, bridges, waterfalls, castles and architectural icons are participating in this year's Shine a Light on NF campaign and will show their support in the global fight...

at 08:10
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health, Inc. , a leading precision oncology company, today announced that on April 22, 2024, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units ("RSUs") representing 215,601 shares of...

at 08:08
Victoria Eye Center/Victoria Surgery Center/Victoria Vision Center Notice of Data Breach
Victoria Eye Center/Victoria Surgery Center/Victoria Vision Center ("VEC") is writing to provide information regarding an event that involves certain information relating to personal health information.  On March 21, 2024, VEC became aware that...

at 08:05
Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting
Azitra, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company's platform and pipeline. The data are being presented on Friday, May 17,...

at 08:05
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Mr. Rosett most recently held the role...

at 08:05
Arcadia Biosciences (RKDA) To Host Investor Call To Discuss Recent Transactions
Arcadia Biosciences, Inc.® , a producer and marketer of innovative, plant-based health and wellness products, today announced that it will host a call for analysts and investors after market close on May 22, 2024. The company has scheduled a...

More news about Health...


News published on and distributed by: